Efficacy and safety of decitabine combined with arsenic trioxide in elderly high-risk myelodysplastic neoplasm patients: a retrospective study.

IF 1.6 4区医学 Q3 HEMATOLOGY

Hematology Pub Date : 2025-12-01 Epub Date: 2025-04-01 DOI:10.1080/16078454.2025.2485493

Jianzhong Yang

{"title":"Efficacy and safety of decitabine combined with arsenic trioxide in elderly high-risk myelodysplastic neoplasm patients: a retrospective study.","authors":"Jianzhong Yang","doi":"10.1080/16078454.2025.2485493","DOIUrl":null,"url":null,"abstract":"Objectives: Elderly patients with high-risk myelodysplastic neoplasm (MDS) face poor outcomes with limited treatment options, often progressing to acute myeloid leukemia (AML). This study investigates the efficacy and safety of combining decitabine (DAC) with arsenic trioxide (ATO) as a novel therapeutic approach.Methods: A retrospective analysis was conducted on 120 elderly high-risk MDS patients, with 52 receiving ATO-DAC (ATO-DAC group) and 68 receiving DAC monotherapy (DAC group). Treatment outcomes were assessed through overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Adverse events were recorded and compared between the two groups.Results: The ATO-DAC group demonstrated a significantly higher ORR of 78.85% compared to 52.94% in the DAC group (P = 0.026). Median PFS was 7.5 months for the ATO-DAC group versus 5.0 months for the DAC group (P = 0.021), and median OS was 14.5 months compared to 11.5 months, respectively (P = 0.034). Although adverse events were more frequent in the ATO-DAC group, the safety profile remained manageable. These findings suggest that the ATO-DAC combination provides superior efficacy compared to DAC monotherapy.Discussion: The combination of DAC and ATO offers a promising and innovative treatment option for elderly high-risk MDS patients, enhancing response rates and survival outcomes while maintaining a manageable safety profile.Conclusion: This study underscores the clinical relevance of this regimen, warranting further investigation in prospective trials.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"30 1","pages":"2485493"},"PeriodicalIF":1.6000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/16078454.2025.2485493","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Elderly patients with high-risk myelodysplastic neoplasm (MDS) face poor outcomes with limited treatment options, often progressing to acute myeloid leukemia (AML). This study investigates the efficacy and safety of combining decitabine (DAC) with arsenic trioxide (ATO) as a novel therapeutic approach.

Methods: A retrospective analysis was conducted on 120 elderly high-risk MDS patients, with 52 receiving ATO-DAC (ATO-DAC group) and 68 receiving DAC monotherapy (DAC group). Treatment outcomes were assessed through overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Adverse events were recorded and compared between the two groups.

Results: The ATO-DAC group demonstrated a significantly higher ORR of 78.85% compared to 52.94% in the DAC group (P = 0.026). Median PFS was 7.5 months for the ATO-DAC group versus 5.0 months for the DAC group (P = 0.021), and median OS was 14.5 months compared to 11.5 months, respectively (P = 0.034). Although adverse events were more frequent in the ATO-DAC group, the safety profile remained manageable. These findings suggest that the ATO-DAC combination provides superior efficacy compared to DAC monotherapy.

Discussion: The combination of DAC and ATO offers a promising and innovative treatment option for elderly high-risk MDS patients, enhancing response rates and survival outcomes while maintaining a manageable safety profile.

Conclusion: This study underscores the clinical relevance of this regimen, warranting further investigation in prospective trials.

查看原文本刊更多论文

地西他滨联合三氧化二砷治疗老年高危骨髓增生异常肿瘤的疗效和安全性回顾性研究

老年高危骨髓增生异常肿瘤（MDS）患者预后不佳，治疗方案有限，通常进展为急性髓系白血病（AML）。本研究探讨地西他滨（DAC）联合三氧化二砷（ATO）作为一种新的治疗方法的有效性和安全性。方法：回顾性分析120例老年高危MDS患者，其中52例接受ATO-DAC治疗（ATO-DAC组），68例接受DAC单药治疗（DAC组）。通过总缓解率（ORR）、无进展生存期（PFS）和总生存期（OS）来评估治疗结果。记录两组患者的不良事件并进行比较。结果：ATO-DAC组的ORR为78.85%，显著高于DAC组的52.94% （P = 0.026）。ATO-DAC组的中位PFS为7.5个月，DAC组为5.0个月（P = 0.021），中位OS分别为14.5个月和11.5个月（P = 0.034）。虽然ATO-DAC组的不良事件更频繁，但安全性仍然可控。这些发现表明，与DAC单药治疗相比，ATO-DAC联合治疗具有更好的疗效。DAC和ATO的联合治疗为老年高危MDS患者提供了一种有前景的创新治疗选择，在保持可管理的安全性的同时提高了应答率和生存结果。结论：该研究强调了该方案的临床相关性，值得在前瞻性试验中进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematology 医学-血液学

CiteScore

2.60

自引率

5.30%

发文量

140

审稿时长

3 months

期刊介绍： Hematology is an international journal publishing original and review articles in the field of general hematology, including oncology, pathology, biology, clinical research and epidemiology. Of the fixed sections, annotations are accepted on any general or scientific field: technical annotations covering current laboratory practice in general hematology, blood transfusion and clinical trials, and current clinical practice reviews the consensus driven areas of care and management.